PAPILLARY RENAL CELL CARCINOMA
Clinical trials for PAPILLARY RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PAPILLARY RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for PAPILLARY RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy shows promise against hard-to-treat kidney cancer
Disease control OngoingThis study tests whether a combination of two drugs, savolitinib and durvalumab, works better than the standard drug sunitinib for people with a rare type of kidney cancer called papillary renal cell carcinoma that has spread. The cancer must have a specific genetic change (MET-d…
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 26, 2026 05:14 UTC
-
New drug combo shows promise for rare kidney cancers
Disease control OngoingThis study tests whether combining two drugs, nivolumab and cabozantinib, can shrink tumors in people with advanced or metastatic non-clear cell kidney cancer. About 60 participants who have had little or no prior treatment will receive the drug combination. The goal is to see ho…
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:11 UTC
-
New drug cocktail shows promise in slowing tough kidney cancers
Disease control OngoingThis study tests whether a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) can safely slow the growth of advanced kidney cancer that has spread. About 60 adults with certain types of kidney cancer that cannot be removed by surgery will receive the treatment. …
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Bradley A. McGregor, MD • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
Could a radioactive drug plus standard therapy ease bone pain in advanced kidney cancer?
Disease control OngoingThis study tests whether adding a radioactive drug (radium-223) to the usual treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 adults with any type of kidney cancer and bone metastases will be randomly assigned to receive ca…
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Head-to-Head drug battle offers hope for rare kidney cancer
Disease control OngoingThis study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug works better at slowing cancer growth and has fewer side effects. About 32 par…
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Can a simple urine test spot kidney cancer? mayo clinic investigates.
Diagnosis OngoingThis study collects blood, tissue, and urine samples from 589 adults with different types of kidney or urinary tract tumors, plus healthy controls. Researchers use advanced DNA sequencing to find unique markers (methylated DNA) that could help detect these cancers earlier. The go…
Matched conditions: PAPILLARY RENAL CELL CARCINOMA
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated May 26, 2026 05:10 UTC